Globally, the electrophysiology and cardiac ablation catheter markets are growing at a steady pace. Individually, the electrophysiology (EP) catheter market value is increasing into 2025, and iData’s analysts predict that the market will reach $2.9 billion. Similarly, the cardiac ablation catheter market is growing and is approaching $3.4 billion by 2025.
What Segments does iData analyze?
Overall, the global report on electrophysiology and cardiac ablation catheters includes,
- Conventional EP catheters
- Advanced EP catheters
- Radiofrequency (RF) cardiac ablation catheters
- Cryoablation catheters
What are electrophysiology and cardiac ablation catheters?
Electrophysiology (EP) ablation is a minimally invasive procedure, which employs catheters to destroy faulty electrical pathways from the heart. Electrophysiology catheters assess the risk of complex arrhythmias, elucidate symptoms, and determine the most appropriate treatment. On the other hand, cardiac ablation catheters create lesions to prevent the propagation of electrical signals that lead to some types of arrhythmias.
What are some of the key market trends?
Overall, both the electrophysiology and cardiac ablation catheter segments within the global cardiac rhythm management market are expected to be the fastest-growing segments of the overall market.
Ever since Biosense Webster received FDA approval for its radiofrequency (RF) catheter, unit growth has accelerated. Catheter ablation is a low-risk process with high success rates, making it the most preferred modality for the treatment of cardiac arrhythmias. As a result of the increasing adoption and use of ablation techniques, EP diagnostic procedures are poised to increase substantially as well. In addition, innovations in wireless and software-based EP diagnostic procedures are attracting investment from hospitals and physicians. By 2025, the number of diagnostic EP catheters sold is increasing, driving growth for the overall market.
In terms of the cardiac ablation catheter segment, there are shifts towards RF ablation catheters and cryoablation catheters. The radiofrequency and cryoablation types are the most widely used EP cardiac ablation catheters and are expected to register significant market capture with pertinent advancements in the technology. In particular, the cryoablation segment is poised to grow at double-digit rates from 2018 to 2025. This growth is attributed to the elimination of disadvantages related to radiofrequency ablation, such as burns from RF, that disrupt the endothelium, tamponades, thromboembolic strokes, and atrial-oesophageal fistula.
What companies compete in these markets?
Among the many competitors within the global market, Biosense Webster is the dominant leader in both markets. Biosense Webster has been competing solely in the EP and cardiac ablation markets, where it has held commanding market-leading positions. The company offers the CARTO®3 3D mapping and EP recording system, SmartAblate® RF ablation generator and remote steering systems, and the nMARQ® RF ablation generator. Accompanying these EP lab systems is a wide portfolio of EP diagnostic catheters and cardiac ablation catheters. Some of the notable product names are the AcuNav™ and CARTO SOUNDSTAR™ ultrasound catheters, the LASSO® advanced EP recording catheters, and the WEBSTER® line of fixed and steerable conventional EP catheters.
Global EP and cardiac ablation catheter Markets: Further Insights
For more information on unit sales, average selling prices (ASPs), procedure volumes, competitive analyses, and more follow the link below to receive a free executive summary for the Global Electrophysiology & Cardiac Ablation Device Market Report. Additionally, iData offers a United States report for cardiac rhythm management, including electrophysiology (EP) and cardiac ablation catheters.